The real effects of Apremilast/Apremilast tablets are revealed, and patient feedback is here!

Apremilast is an oral drug used to treat moderate to severe plaque psoriasis and psoriatic arthritis (PSA). Its mechanism of action is mainly by inhibiting phosphodiesterase 4 (PDE4), thereby regulating the inflammatory response. Psoriasis is a chronic, relapsing skin disease that seriously affects patients' quality of life, so it is important to find effective treatments. In this regard, Apremilast, as a new treatment option, has shown good efficacy and safety.

In clinical studies, Apremilast has been shown to be effective in reducing the severity of psoriasis, as demonstrated through multiple randomized controlled trials. These trials usually last 52 weeks and evaluate efficacy by observing the extent of skin lesions and improvement in patients' quality of life. The results showed that Apremilast can significantly reduce the area of u200bu200bskin lesions and improve the patient's quality of life. The patient's symptoms were significantly relieved after receiving treatment. At the same time, during follow-up after drug discontinuation, some patients were able to quickly regain their original response after restarting apremilast treatment, indicating that the drug has good flexibility and effectiveness in the long-term management of psoriasis.

Regarding the safety of the drug, Apremilast is generally considered well tolerated. Especially early in treatment, patients may experience mild side effects such as diarrhea, nausea, and weight loss, but these usually resolve on their own within a few weeks. Additionally, psoriasis itself is known to have a negative impact on patients' mental health, although some research suggests that Apremilast use may be associated with an increased risk of depression. Therefore, during the treatment process, medical staff should pay close attention to the patient's psychological state to ensure adequate support and intervention.

Apremilast offers a more convenient route of administration than traditional psoriasis treatments. Many patients face application inconvenience or poor compliance when receiving topical treatments, especially in difficult-to-apply locations such as the scalp. The oral delivery form makes the treatment more convenient for patients, making Apremilast an attractive alternative, especially for those who are strongly resistant to injection treatments. In addition, use of Apremilast does not require routine laboratory monitoring, further reducing patient burden during treatment.

Economic analysis also shows that Apremire performs well in terms of cost-effectiveness. Compared to some biologics, Apremilast's relatively low cost and relatively few side effects make it the first choice for many patients. Systemic drugs to treat psoriasis are often expensive, and the introduction of Apremilast allows more patients to receive timely and effective treatment, thereby improving the economic efficiency of the entire healthcare system.

In conclusion, apremilast, as a new oral drug, has demonstrated good efficacy and safety in the treatment of moderate to severe plaque psoriasis. Its unique mode of administration and high tolerability make it an ideal choice for patients. At the same time, considering its economic advantages, Apremilast is expected to occupy an important position in the future of psoriasis treatment.

Reference materials:https://www.dovepress.com/apremilast-in-the-treatment-of-plaque-psoriasis-differential-use-in-ps-peer-reviewed-fulltext-article-CCID